Efficacy and safety of teclistamab followed by autologous stem cells transplant in functional high-risk and triple class refractory multiple myeloma. Mediterr J Hematol Infect Dis [Internet]. 2025 Jun. 29 [cited 2026 May 1];17(1):e2025051. Available from: https://www.mjhid.org/mjhid/article/view/5994